FY2022 EPS Estimates for Forty Seven Inc (FTSV) Increased by Analyst

Forty Seven Inc (NASDAQ:FTSV) – Oppenheimer boosted their FY2022 earnings per share estimates for Forty Seven in a report issued on Wednesday, November 14th. Oppenheimer analyst M. Breidenbach now forecasts that the company will post earnings of $1.94 per share for the year, up from their prior forecast of $1.88. Oppenheimer currently has a “Outperform” rating and a $35.00 price target on the stock.

A number of other brokerages have also recently commented on FTSV. Morgan Stanley assumed coverage on shares of Forty Seven in a research note on Monday, July 23rd. They set an “overweight” rating and a $25.00 price objective on the stock. Credit Suisse Group assumed coverage on shares of Forty Seven in a research note on Monday, July 23rd. They set an “outperform” rating and a $24.00 price objective on the stock. Canaccord Genuity assumed coverage on shares of Forty Seven in a research note on Monday, July 23rd. They set a “buy” rating and a $22.00 price objective on the stock. Zacks Investment Research raised shares of Forty Seven from a “sell” rating to a “hold” rating in a research note on Thursday, October 4th. Finally, ValuEngine raised shares of Forty Seven from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Forty Seven has a consensus rating of “Buy” and an average target price of $26.75.

Shares of NASDAQ FTSV opened at $12.53 on Thursday. Forty Seven has a 12 month low of $12.02 and a 12 month high of $16.86.

Forty Seven (NASDAQ:FTSV) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.17).

Several large investors have recently made changes to their positions in the company. Point72 Hong Kong Ltd purchased a new position in shares of Forty Seven during the 2nd quarter valued at approximately $120,000. Janus Henderson Group PLC purchased a new position in shares of Forty Seven during the 2nd quarter valued at approximately $160,000. DAFNA Capital Management LLC purchased a new position in shares of Forty Seven during the 2nd quarter valued at approximately $160,000. Waddell & Reed Financial Inc. purchased a new position in shares of Forty Seven during the 2nd quarter valued at approximately $160,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Forty Seven during the 3rd quarter valued at approximately $196,000. Hedge funds and other institutional investors own 41.08% of the company’s stock.

In other Forty Seven news, major shareholder Ravi Mhatre bought 166,858 shares of the firm’s stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average price of $15.08 per share, for a total transaction of $2,516,218.64. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Peter Nieh bought 67,500 shares of the firm’s stock in a transaction dated Friday, August 17th. The shares were acquired at an average price of $15.18 per share, for a total transaction of $1,024,650.00. The disclosure for this purchase can be found here.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.

Further Reading: Why Dividend Stocks May Be Right for You

Earnings History and Estimates for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply